madman
Super Moderator
(073) The Effects of Intranasal Testosterone (Natesto™) for Treatment of Hypogonadism on Maintenance of Spermatogenesis: Demographic Data from a Single-Institution, Prospective, Non-blinded Study
AbstractIntroduction. Testosterone therapy (TTh) is becoming increasingly common among men of reproductive age in the United States. An estimated 3 million
academic.oup.com
The study investigates the effects of Natesto™, an intranasal testosterone gel, on hypogonadal symptoms and spermatogenesis in men on gonadotropin therapy. The objective is to assess changes in total motile sperm count, LH, FSH, testosterone, estrogen, and quality of life measurements over a 26-week period. Male patients diagnosed with testosterone-induced hypo-spermatogenesis discontinued intramuscular testosterone therapy and started gonadotropin therapy along with Natesto™. Hormone profiles, questionnaires, and semen analysis were conducted at baseline, 14 weeks, and 26 weeks. The study aims to confirm Natesto™'s role in relieving symptoms while preserving spermatogenesis recovery.
Key takeaways:
- A total of 9 patients participated in the study, with 4 patients completing the baseline assessments and follow-up visits.
- Demographic data of the patients included a median age of 35, LH of 3.15, FSH of 3.2, a testosterone level of 260ng/dl, IIEF score of 20, SF-36 energy/fatigue score of 42.5%, and ADAM score of 5.5.
- Four patients achieved gonadotropin suppression, and 6 patients were azoospermic (no sperm present in semen).
- Interval semen analyses showed an increase in total motile sperm count for some patients, while persistent azoospermia was observed in 2 patients.
- Mean testosterone levels increased by 297.5ng/dl.
- No adverse events were reported by the patients.
- Preliminary results suggest that cessation of testosterone therapy for spermatogenesis restoration can lead to decreased sexual and overall function scores.
- Continued research with a larger sample size is necessary to gather more conclusive data on the effects of Natesto™ therapy on hypogonadal symptoms during testosterone therapy cessation